Mitchell J, Gillette M
Front Neurosci. 2023; 17:1196606.
PMID: 37732312
PMC: 10507717.
DOI: 10.3389/fnins.2023.1196606.
Humphreys S, Whyte C, Mutch N
Front Cardiovasc Med. 2023; 10:1146833.
PMID: 37153474
PMC: 10155837.
DOI: 10.3389/fcvm.2023.1146833.
Eruysal E, Ravdin L, Zhang C, Kamel H, Iadecola C, Ishii M
J Alzheimers Dis. 2022; 91(3):1073-1083.
PMID: 36565112
PMC: 10518184.
DOI: 10.3233/JAD-220686.
Schol-Gelok S, de Maat M, Biedermann J, van Gelder T, Leebeek F, Lijfering W
Br J Haematol. 2020; 190(6):916-922.
PMID: 32301122
PMC: 7539918.
DOI: 10.1111/bjh.16648.
Messa G, La Placa G, Puccetti L, Acciavatti A, Provvedi T, Palazzini E
Clin Drug Investig. 2016; 10(3):165-71.
PMID: 27519200
DOI: 10.2165/00044011-199510030-00005.
Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
Tofler G, Massaro J, ODonnell C, Wilson P, Vasan R, Sutherland P
Thromb Res. 2016; 140:30-35.
PMID: 26896607
PMC: 5722217.
DOI: 10.1016/j.thromres.2016.02.002.
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.
Lalic K, Jotic A, Rajkovic N, Singh S, Stosic L, Popovic L
Int J Endocrinol. 2015; 2015:390185.
PMID: 26089884
PMC: 4451778.
DOI: 10.1155/2015/390185.
Effect of growth hormone on plasminogen activator and inhibitor activity in rat.
Bubber P, Sharma A, Chauhan A, Bansal D
Indian J Clin Biochem. 2014; 28(2):193-6.
PMID: 24426209
PMC: 3613504.
DOI: 10.1007/s12291-012-0249-0.
Human circadian system causes a morning peak in prothrombotic plasminogen activator inhibitor-1 (PAI-1) independent of the sleep/wake cycle.
Scheer F, Shea S
Blood. 2013; 123(4):590-3.
PMID: 24200683
PMC: 3901072.
DOI: 10.1182/blood-2013-07-517060.
Chronopharmacology: new insights and therapeutic implications.
Dallmann R, Brown S, Gachon F
Annu Rev Pharmacol Toxicol. 2013; 54:339-61.
PMID: 24160700
PMC: 3885389.
DOI: 10.1146/annurev-pharmtox-011613-135923.
Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.
Tjarnlund-Wolf A, Brogren H, Lo E, Wang X
Stroke. 2012; 43(10):2833-9.
PMID: 22879095
PMC: 3712849.
DOI: 10.1161/STROKEAHA.111.622217.
Antineoplastic agent busulfan regulates a network of genes related to coagulation and fibrinolysis.
Reimer J, Bien S, Ameling S, Hammer E, Volker U, Hempel G
Eur J Clin Pharmacol. 2012; 68(6):923-35.
PMID: 22286157
DOI: 10.1007/s00228-011-1209-y.
Plasma fibrinogen, tissue plasminogen activator, plasminogen activator inhibitor 1, and their related factors in three Japanese population samples.
Koike K, Iso H, Shimamoto T, Kudo M, Umemura U, Sato S
Environ Health Prev Med. 2011; 3(3):158-63.
PMID: 21432496
PMC: 2723365.
DOI: 10.1007/BF02931707.
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort....
Yajima K, Shimada A, Hirose H, Oikawa Y, Yamada S, Meguro S
Clin Drug Investig. 2009; 29(12):811-9.
PMID: 19888787
DOI: 10.2165/11530610-000000000-00000.
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
Fogari R, Preti P, Lazzari P, Corradi L, Zoppi A, Fogari E
Eur J Clin Pharmacol. 2003; 59(4):271-5.
PMID: 12830340
DOI: 10.1007/s00228-003-0621-3.
Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.
Kemme M, Schoemaker R, Burggraaf J, van der Linden M, Noordzij M, Moerland M
J Pharmacokinet Pharmacodyn. 2003; 30(1):3-22.
PMID: 12800805
DOI: 10.1023/a:1023293325245.
Quantification of heparin-induced TFPI release: a maximum release at low heparin dose.
Kemme M, Burggraaf J, Schoemaker R, Kluft C, Cohen A
Br J Clin Pharmacol. 2002; 54(6):627-34.
PMID: 12492611
PMC: 1874485.
DOI: 10.1046/j.1365-2125.2002.t01-1-01705.x.
Effect of a Change in the Sleep/Wake Cycle on the Diurnal Variation of Fibrinolytic Parameters.
Irokawa , Nishinaga , Funayama , Ikeda , Shimada
J Thromb Thrombolysis. 2000; 5(2):165-168.
PMID: 10767112
DOI: 10.1023/A:1008838330924.
Hemostatic abnormalities and the severity of illness in patients at the onset of clinically defined sepsis. Possible indication of the degree of endothelial cell activation?.
Leithauser B, Matthias F, Nicolai U, Voss R
Intensive Care Med. 1996; 22(7):631-6.
PMID: 8844226
DOI: 10.1007/BF01709738.
Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers.
Wallen N, Larsson P, Broijersen A, Andersson A, Hjemdahl P
Br J Clin Pharmacol. 1993; 35(2):143-51.
PMID: 8443032
PMC: 1381505.
DOI: 10.1111/j.1365-2125.1993.tb05680.x.